Developmental Therapeutics and Pharmacology Unit

One of the major obstacles to effectively treating central nervous system (CNS) tumors is the integrity of the blood-brain barrier (BBB). The BBB prevents systemic drug delivery from reaching the brain and brain tumor tissue. While previous studies have focused on circumventing the BBB, suing direct tumor delivery, very few agents or mechanisms to modulate the tumor microenvironment to enhance effective therapies for CNS brain tumors. Dr. Sadhana Jackson’s studies focus on understanding the heterogeneity of BBB permeability amongst malignant pediatric brain tumors. Her laboratory and clinical studies pertain to comprehensive evaluation of BBB biology, pharmacokinetics and pharmacodynamics involved in relation to optimal CNS drug delivery.

Lab Members:

  • Amelie Vezina, PhD, Post-Doctoral Visiting Fellow
  • Crystal Burgess, Post-Baccalaureate IRTA
  • Brandon Foster, Post-Baccalaureate IRTA

Selected Publications: